BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

281 related articles for article (PubMed ID: 36485001)

  • 1. Tumor-Infiltrating Lymphocyte Therapy in Melanoma: Facts to the Future.
    Betof Warner A; Corrie PG; Hamid O
    Clin Cancer Res; 2023 May; 29(10):1835-1854. PubMed ID: 36485001
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Adoptive T-cell therapy using autologous tumor-infiltrating lymphocytes for metastatic melanoma: current status and future outlook.
    Wu R; Forget MA; Chacon J; Bernatchez C; Haymaker C; Chen JQ; Hwu P; Radvanyi LG
    Cancer J; 2012; 18(2):160-75. PubMed ID: 22453018
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Long-Lasting Complete Responses in Patients with Metastatic Melanoma after Adoptive Cell Therapy with Tumor-Infiltrating Lymphocytes and an Attenuated IL2 Regimen.
    Andersen R; Donia M; Ellebaek E; Borch TH; Kongsted P; Iversen TZ; Hölmich LR; Hendel HW; Met Ö; Andersen MH; Thor Straten P; Svane IM
    Clin Cancer Res; 2016 Aug; 22(15):3734-45. PubMed ID: 27006492
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Prior Treatment on the Efficacy of Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma.
    Seitter SJ; Sherry RM; Yang JC; Robbins PF; Shindorf ML; Copeland AR; McGowan CT; Epstein M; Shelton TE; Langhan MM; Franco Z; Danforth DN; White DE; Rosenberg SA; Goff SL
    Clin Cancer Res; 2021 Oct; 27(19):5289-5298. PubMed ID: 34413159
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of lifileucel, a one-time autologous tumor-infiltrating lymphocyte (TIL) cell therapy, in patients with advanced melanoma after progression on immune checkpoint inhibitors and targeted therapies: pooled analysis of consecutive cohorts of the C-144-01 study.
    Chesney J; Lewis KD; Kluger H; Hamid O; Whitman E; Thomas S; Wermke M; Cusnir M; Domingo-Musibay E; Phan GQ; Kirkwood JM; Hassel JC; Orloff M; Larkin J; Weber J; Furness AJS; Khushalani NI; Medina T; Egger ME; Graf Finckenstein F; Jagasia M; Hari P; Sulur G; Shi W; Wu X; Sarnaik A
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36600653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adoptive cell therapy using tumor-infiltrating lymphocytes for melanoma refractory to immune-checkpoint inhibitors.
    Hirai I; Funakoshi T; Kamijuku H; Fukuda K; Mori M; Sakurai M; Koda Y; Kato J; Mori T; Watanabe N; Noji S; Yaguchi T; Iwata T; Ohta S; Fujita T; Tanosaki R; Handa M; Okamoto S; Amagai M; Kawakami Y
    Cancer Sci; 2021 Aug; 112(8):3163-3172. PubMed ID: 34101300
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Durable complete responses in heavily pretreated patients with metastatic melanoma using T-cell transfer immunotherapy.
    Rosenberg SA; Yang JC; Sherry RM; Kammula US; Hughes MS; Phan GQ; Citrin DE; Restifo NP; Robbins PF; Wunderlich JR; Morton KE; Laurencot CM; Steinberg SM; White DE; Dudley ME
    Clin Cancer Res; 2011 Jul; 17(13):4550-7. PubMed ID: 21498393
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Achievements and challenges of adoptive T cell therapy with tumor-infiltrating or blood-derived lymphocytes for metastatic melanoma: what is needed to achieve standard of care?
    Svane IM; Verdegaal EM
    Cancer Immunol Immunother; 2014 Oct; 63(10):1081-91. PubMed ID: 25099366
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Surgical Considerations for Tumor Tissue Procurement to Obtain Tumor-Infiltrating Lymphocytes for Adoptive Cell Therapy.
    Mullinax JE; Egger ME; McCarter M; Monk BJ; Toloza EM; Brousseau S; Jagasia M; Sarnaik A
    Cancer J; 2022 Jul-Aug 01; 28(4):285-293. PubMed ID: 35880938
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adoptive transfer of tumor-infiltrating lymphocytes in melanoma: a viable treatment option.
    Rohaan MW; van den Berg JH; Kvistborg P; Haanen JBAG
    J Immunother Cancer; 2018 Oct; 6(1):102. PubMed ID: 30285902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CD8+ enriched "young" tumor infiltrating lymphocytes can mediate regression of metastatic melanoma.
    Dudley ME; Gross CA; Langhan MM; Garcia MR; Sherry RM; Yang JC; Phan GQ; Kammula US; Hughes MS; Citrin DE; Restifo NP; Wunderlich JR; Prieto PA; Hong JJ; Langan RC; Zlott DA; Morton KE; White DE; Laurencot CM; Rosenberg SA
    Clin Cancer Res; 2010 Dec; 16(24):6122-31. PubMed ID: 20668005
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.
    Saberian C; Amaria RN; Najjar AM; Radvanyi LG; Haymaker CL; Forget MA; Bassett RL; Faria SC; Glitza IC; Alvarez E; Parshottam S; Prieto V; Lizée G; Wong MK; McQuade JL; Diab A; Yee C; Tawbi HA; Patel S; Shpall EJ; Davies MA; Hwu P; Bernatchez C
    J Immunother Cancer; 2021 May; 9(5):. PubMed ID: 34021033
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expert consensus guidelines on management and best practices for tumor-infiltrating lymphocyte cell therapy.
    Betof Warner A; Hamid O; Komanduri K; Amaria R; Butler MO; Haanen J; Nikiforow S; Puzanov I; Sarnaik A; Bishop MR; Schoenfeld AJ
    J Immunother Cancer; 2024 Feb; 12(2):. PubMed ID: 38423748
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical responses in a phase II study using adoptive transfer of short-term cultured tumor infiltration lymphocytes in metastatic melanoma patients.
    Besser MJ; Shapira-Frommer R; Treves AJ; Zippel D; Itzhaki O; Hershkovitz L; Levy D; Kubi A; Hovav E; Chermoshniuk N; Shalmon B; Hardan I; Catane R; Markel G; Apter S; Ben-Nun A; Kuchuk I; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2010 May; 16(9):2646-55. PubMed ID: 20406835
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modeling
    Knochelmann HM; Rivera-Reyes AM; Wyatt MM; Smith AS; Chamness R; Dwyer CJ; Bobian M; Rangel Rivera GO; Horton JD; Lilly M; Romeo MJ; Timmers CD; Rubinstein MP; Neskey DM; Paulos CM
    Oncoimmunology; 2021; 10(1):1959101. PubMed ID: 34408920
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Key Factors in Clinical Protocols for Adoptive Cell Therapy in Melanoma.
    Considine B; Hurwitz ME
    Methods Mol Biol; 2020; 2097():309-327. PubMed ID: 31776935
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Predictors of tumor-infiltrating lymphocyte efficacy in melanoma.
    Zikich D; Schachter J; Besser MJ
    Immunotherapy; 2016; 8(1):35-43. PubMed ID: 26653685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adoptive transfer of tumor-infiltrating lymphocytes in patients with metastatic melanoma: intent-to-treat analysis and efficacy after failure to prior immunotherapies.
    Besser MJ; Shapira-Frommer R; Itzhaki O; Treves AJ; Zippel DB; Levy D; Kubi A; Shoshani N; Zikich D; Ohayon Y; Ohayon D; Shalmon B; Markel G; Yerushalmi R; Apter S; Ben-Nun A; Ben-Ami E; Shimoni A; Nagler A; Schachter J
    Clin Cancer Res; 2013 Sep; 19(17):4792-800. PubMed ID: 23690483
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-infiltrating lymphocytes in melanoma.
    Lee S; Margolin K
    Curr Oncol Rep; 2012 Oct; 14(5):468-74. PubMed ID: 22878966
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor infiltrating lymphocytes (TIL) therapy in metastatic melanoma: boosting of neoantigen-specific T cell reactivity and long-term follow-up.
    van den Berg JH; Heemskerk B; van Rooij N; Gomez-Eerland R; Michels S; van Zon M; de Boer R; Bakker NAM; Jorritsma-Smit A; van Buuren MM; Kvistborg P; Spits H; Schotte R; Mallo H; Karger M; van der Hage JA; Wouters MWJM; Pronk LM; Geukes Foppen MH; Blank CU; Beijnen JH; Nuijen B; Schumacher TN; Haanen JBAG
    J Immunother Cancer; 2020 Aug; 8(2):. PubMed ID: 32753545
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.